Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PARP 1/2 inhibitor TQB3823

An orally bioavailable, small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon oral administration, PARP 1/2 inhibitor TQB3823 selectively binds to and inhibits PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	PARP inhibitor TQB3823
Code name:	TQB 3823 TQB-3823 TQB3823

PARP 1/2 inhibitor TQB3823

Search NCI's Drug Dictionary